Akhtar M, Jazayeri M, Sra J, Tchou P, Rovang K, Blanck Z, Dhala A, Deshpande S, Axtell K
Electrophysiology Laboratory, Sinai Samaritan Medical Center, Milwaukee, Wisconsin 53233.
Pacing Clin Electrophysiol. 1993 Mar;16(3 Pt 2):511-8. doi: 10.1111/j.1540-8159.1993.tb01618.x.
Among the various therapy options for survivors of ventricular tachycardia-ventricular fibrillation (VT-VF), the implantable cardioverter defibrillator (ICD) seems most promising. It reliably terminates VT-VF and thus significantly impacts sudden cardiac death (SCD) survival. It is more effective than any of the known antiarrhythmic drugs in prevention of SCD, particularly among survivors of cardiac arrest. Compared to VT surgery, the ICD therapy can be offered to a larger pool of patients and can be placed at a lower surgical risk. With proper patient selection, ICD therapy is of major benefits to its recipients since it markedly reduces the chances of VT-VF related mortality; the main cause of premature death in this population. The ICD therapy is cost effective when compared to other medical interventions and could be more so if the implant is carried out early in the course of VT-VF management.
在室性心动过速-心室颤动（VT-VF）幸存者的各种治疗选择中，植入式心脏复律除颤器（ICD）似乎最具前景。它能可靠地终止VT-VF，从而对心脏性猝死（SCD）的生存率产生显著影响。在预防SCD方面，它比任何已知的抗心律失常药物都更有效，尤其是在心脏骤停幸存者中。与VT手术相比，ICD治疗可应用于更多患者，且手术风险更低。通过适当的患者选择，ICD治疗对接受者有重大益处，因为它显著降低了VT-VF相关死亡率的几率；而这是该人群过早死亡的主要原因。与其他医疗干预措施相比，ICD治疗具有成本效益，如果在VT-VF管理过程中尽早进行植入，可能更具成本效益。
